Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Amicus Therapeutics (FOLD) Asset Writedowns and Impairment (2017 - 2023)

Amicus Therapeutics filings provide 3 years of Asset Writedowns and Impairment readings, the most recent being $1.1 million for Q2 2023.

On a quarterly basis, Asset Writedowns and Impairment changed N/A to $1.1 million in Q2 2023 year-over-year; TTM through Dec 2023 was $1.1 million, a 82.86% decrease, with the full-year FY2025 number at $1.7 million, down 81.52% from a year prior.
Asset Writedowns and Impairment hit $1.1 million in Q2 2023 for Amicus Therapeutics, down from $6.6 million in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $6.6 million in Q1 2022 to a low of $1.1 million in Q2 2023.